Ministerio de Ciencia e Innovación

Precision Diagnostics and Therapies

Coordinator: Enrique de Álava/ Co-coordinator: Ignacio Melero

The determination of biomarkers in tumor tissue and peripheral blood provides critical information that can predict cancer patients' likelihood of responding to various treatments, such as those based on targeted therapies or immunotherapies. The ultimate goal is to guide patients toward the best available or experimental treatment on a personalized basis.

This program leverages the potential of 7 research groups to identify and validate new biomarkers in tissue and liquid biopsy for the clinical development of therapies that can be applied to the pathologies represented in CIBERONC's vertical programs.

Program objectives:

  • Discovery and clinical validation of immune biomarkers for precision medicine through CIBERONC's vertical programs (liquid biopsy, digital pathology, clinical biomarkers, immunology techniques).
  • Development and study of preclinical experimental models to understand mechanisms and biomarkers associated with the benefit or lack of benefit from immunotherapies and other treatment modalities, including combination strategies.
  • Support to other programs with technology provided by the Working Groups.


Main researcherConsortium InstitutionsRegions
Enrique de Álava Hospital Virgen del Rocío-IBiS Andalucía
Ignacio Melero Clínica Universidad de Navarra Navarra
F. Xavier Matías-Guíu Instituto de Investigación Biomédica de Lleida Cataluña
Rafael López López Complejo Hospitalario Universitario de Santiago Galicia
Santiago Ramón Y Cajal Intituto de Investigación Vall d'Hebron Cataluña
María Jesús Vicent Centro de Investigación Príncipe Felipe Valencia
Rosa Noguera Instituto de Investigación Sanitaria INCLIVA Valencia